RxDoctor Payments Data

Nidhi Huff, MD

Pulmonary Disease · Austell, GANPI 1659515864

Payments from drug & device makers

$4,751in general payments, 2019–2025

Across 224 payments — averaging $21.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$872
  • GSK$621
  • Sanofi$372
  • AstraZeneca$324
  • Grifols USA, LLC$269
  • Sunovion Pharmaceuticals Inc.$189
  • plus $2K from 39 others

What the payments were for

  • Food & beverage$4,749100%
  • Education$30%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,751 in reported general payments places this provider in the 45th percentile of 365 pulmonary disease providers in Georgia.

See all pulmonary disease providers in Georgia

Medicare billing

Part B allowed, 2024
$54,718
Medicare patients
231
Services billed
564

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter222$158,583
Breo ElliptaFluticasone/Vilanterol122$61,600
Breztri AerosphereBudesonide/Glycopyr/Formoterol58$36,109
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr70$34,343
EliquisApixaban43$32,768
Stiolto RespimatTiotropium Br/Olodaterol Hcl35$24,043
Advair HfaFluticasone Propion/Salmeterol40$16,899
Albuterol Sulfate HfaAlbuterol Sulfate270$9,897
SymbicortBudesonide/Formoterol Fumarate15$5,531
Fluticasone-SalmeterolFluticasone Propion/Salmeterol48$5,419
Roflumilast33$3,222
Wixela InhubFluticasone Propion/Salmeterol19$3,036
Ventolin HfaAlbuterol Sulfate46$2,892
Levalbuterol Tartrate HfaLevalbuterol Tartrate20$1,170
Montelukast Sodium146$1,032

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$621$254,526414 claims
AstraZenecaBreztri Aerosphere, Symbicort$324$41,64073 claims
Boehringer IngelheimStiolto Respimat$872$24,04335 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 365 pulmonary disease providers in Georgia.

Other pulmonary disease in Austell

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →